Hepregen Corporation

The mission of Hepregen Corporation is to transform safety assessment and drug development in order to significantly impact patients’ lives. The company is focused on advancing and commercializing its microliver platform, HepatoPac, into the drug-development pipeline of pharmaceutical and biotechnology companies. We have utilized microtechnology tools adapted from the semiconductor industry to both optimize and miniaturize in multi-well formats an in vitro model of the human liver called HepatoPac, a micro-patterned co-culture (MPCC). Specifically, human hepatocytes are organized into colonies of prescribed, optimized dimensions using microfabrication tools and subsequently surrounded by supportive, non- parenchymal cells. Hepatocytes in HepatoPac retain their in vivo-like morphology, express liver genes, metabolize com- pounds using active Phase I and Phase II drug metabolism enzymes, secrete diverse liver‐specific products, and display functional bile canaliculi for up to 4 weeks in vitro Hepr